Hepatitis C virus RNA in serum as a risk factor for isoniazid hepatotoxicity [4]

Infection

Volumn 35, Issue 4, 2007, Pages 295-297

  Fernandez Villar A ^a   Sopena B ^a   Garcia J ^b   Gimena, B ^a   Ulloa, F ^a   Botana, M ^c   Martinez Vazquez C ^a  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^b Servicio de Microbiología   (Spain)

^c UNIVERSITY OF VIGO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DISEASE MARKER; FEMALE; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LETTER; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; RNA BINDING; SERODIAGNOSIS; SIDE EFFECT; SPUTUM SMEAR; TUBERCULIN TEST; TUBERCULOSIS; VIRUS REPLICATION;

ADULT; ANTITUBERCULAR AGENTS; FEMALE; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HEPATITIS, TOXIC; HUMANS; ISONIAZID; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS; PROSPECTIVE STUDIES; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 34547691045     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-007-6125-9     Document Type: Letter

References (12)

1. Sabin CA: Pitfall of assessing hepatotoxicity in trials and observational cohorts. Clin Infect Dis 2004; 38: S56-S64.
2. Fernández-Villar A, Sopeña B, Vázquez R, Ulloa F, Fluiters F, Mosteiro M, et al. Isoniazid hepatotoxicity among drug users. The role of hepatitis C. Clin Infect Dis 2003; 36: 293-298.
3. Pawlotsky JM: Use and interpretation of virological test for hepatitis C. Hepatology 2002; 36: S65-S63.
4. Sadaphal P, Astemborski J, Graham NMH, Sheely L, Bonds M, Madison A, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis 2001; 33: 1687-1691.
5. Ungo J, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE: Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157: 1871-1876.
6. Schenker S, Martin RR, Hoyumpa A: Antecedent liver disease and drug toxicity. J Hepatol 1999; 31: 1098-1105.
7. Fernández-Villar A, Sopeña B, Fernández-Villar J, Vázquez-Gallardo R, Ulloa F, Leiro V, et al. The influence of risk factors on the severity of antituberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2004; 8: 1499-1505.
8. Sylvestre D, Clements BJ: The utility of indirect predictors of hepatitis C viremia. Drug Alcohol Depend 2004; 74: 5-9.
9. Jauncey M, Micallef JM, Gilmar S, Amin J, White PA, Rawlinson W, et al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis 2004; 190: 1270-1274.
10. Patel PA, Voigt MD: Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002; 97: 1198-1203.
11. Wu JC, Lee SD, Yeh PF, Chan CY, Wang YJ, Huang YTT, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98: 502-504.
12. Bonacini M: Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clin Infect Dis 2004; 38: S104-S108.